NewsBenzingaTransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138 TransCode Therapeutics' Board Initiates A Formal Strategic Process To Evaluate Opportunities Designed To Maximize The Value Of The Company And Its Oncology Portfolio, Including Its Lead Product Candidate, TTX-MC138 Benzinga 2026.10.28 20:42 (GMT+0) Open on Benzinga Other news Freedom Broker Maintains Buy on XPeng, Lowers Price Target to $20 Plug Power Shares Slide Toward 52-Week Low Despite New 280-MW Texas Deal Nvidia Vs. Anthropic: Can the AI IPO Challenge Nvidia’s Dominance Across ETFs? Freedom Broker Maintains Buy on Allot, Lowers Price Target to $12.7 Freedom Broker Upgrades M-Tron Industries to Buy, Lowers Price Target to $84 As decision model use skyrockets, is customization is the next frontier?